Skip to main content

Austedo Dosage

Generic name: DEUTETRABENAZINE 6mg
Dosage form: tablet, coated
Drug class: VMAT2 inhibitors

Medically reviewed by Last updated on May 17, 2022.

Dosing Information

The dose of AUSTEDO is determined individually for each patient based on reduction of chorea or tardive dyskinesia and tolerability. When first prescribed to patients who are not being switched from tetrabenazine (a related VMAT2 inhibitor), the recommended starting dosage of AUSTEDO is 12 mg per day (6 mg twice daily) for patients with Huntington’s disease or tardive dyskinesia.

  • The dose of AUSTEDO may be increased at weekly intervals in increments of 6 mg per day based on reduction of chorea or tardive dyskinesia and tolerability, up to a maximum recommended daily dosage of 48 mg [see Clinical Trials 14.1, 14.2)].
  • Administer total daily dosages of 12 mg or above in two divided doses.
  • Administer AUSTEDO with food [see Clinical Pharmacology (12.3)].
  • Swallow AUSTEDO whole. Do not chew, crush, or break tablets.

Switching Patients from Tetrabenazine (XENAZINE®) to AUSTEDO

Discontinue tetrabenazine (XENAZINE®) and initiate AUSTEDO the following day. The recommended initial dosing regimen of AUSTEDO in patients switching from tetrabenazine (XENAZINE®) to AUSTEDO is shown in Table 1.

Table 1: Recommended Initial Dosing Regimen when Switching from Tetrabenazine (XENAZINE®) to AUSTEDO
Current tetrabenazine
daily dosage
Initial regimen of

12.5 mg

6 mg once daily

25 mg

6 mg twice daily

37.5 mg

9 mg twice daily

50 mg

12 mg twice daily

62.5 mg

15 mg twice daily

75 mg

18 mg twice daily

87.5 mg

21 mg twice daily

100 mg

24 mg twice daily

After patients are switched to AUSTEDO, the dose may be adjusted at weekly intervals [see Dosage and Administration (2.1)].

Dosage Adjustment with Strong CYP2D6 Inhibitors

In patients receiving strong CYP2D6 inhibitors (e.g., quinidine, antidepressants such as paroxetine, fluoxetine, and bupropion), the total daily dosage of AUSTEDO should not exceed 36 mg (maximum single dose of 18 mg) [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].

Dosage Adjustment in Poor CYP2D6 Metabolizers

In patients who are poor CYP2D6 metabolizers, the total daily dosage of AUSTEDO should not exceed 36 mg (maximum single dose of 18 mg) [see Use in Specific Populations (8.7)].

Discontinuation and Interruption of Treatment

Treatment with AUSTEDO can be discontinued without tapering. Following treatment interruption of greater than one week, AUSTEDO therapy should be re-titrated when resumed. For treatment interruption of less than one week, treatment can be resumed at the previous maintenance dose without titration.

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.